GLPG1690-CL-304 A Phase 3 randomized double blind parallel group, placebo controlled multicenter study to evaluate efficacy and safety of 2 doses of GLPG1690 in addition to local standard of care

Administered By

Awarded By

Contributors

Start/End

  • May 6, 2019 - April 30, 2023